Unichem Laboratories Limited (UNICHEMLAB) Fair Value & Analysis
Healthcare · IN · Market cap ₹32.8B
Fair value as of: Jul 3, 2026
From 17 valuation models · updated today
Share price +27.1% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹284.05 – ₹645.50 · fair‑value band ₹331.11 – ₹555.42 · the ₹473.00 price screens above the ₹364.18 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Unichem Laboratories Limited (UNICHEMLAB) currently trades at ₹473.00, while our model-based Fair Value estimate is ₹364.18 — implying the stock looks roughly 23.0% overvalued today. We read business quality at 53/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Unichem Laboratories Limited generated revenue of ₹22.0B at a net margin of 11.5%. Revenue declined 2.1% year over year. It earns a return on equity of 9.8%. Net debt stands at ₹2.1B. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Unichem Laboratories Limited, a pharmaceutical company, manufactures and sells pharmaceutical products in India, the United States, and internationally. The company offers formulation products that address various therapeutic areas, such as gastroenterology, cardiology, diabetology, psychiatry, neurology, anti-bacterial, anti-infective, and pain management. It also offers active pharmaceutical ingredients, as well as contract manufacturing services. In addition, the company manufactures allopathic medicines, bulk drugs, and chemicals. It serves patients, distributors, health care professionals, and government institutions. The company was founded in 1944 and is based in Mumbai, India. Unichem Laboratories Limited is a subsidiary of Ipca Laboratories Limited.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Unichem Laboratories Limited reported revenue of ₹22.0B in FY2026 versus ₹12.6B in FY2022, a compound +15.1%/yr. Reported net income was ₹2.5B in FY2026, compounding +66.3%/yr from FY2022.
Is UNICHEMLAB fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$24.45 | R$6.33 | -74% |
| Hansoh Pharmaceutical Group 3692 | HK$29.32 | HK$23.94 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,623 | ₹1,461 | -78% |
| Swedish Orphan Biovitrum AB SOBI | kr 446.60 | kr 234.19 | -48% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Unichem Laboratories Limited (UNICHEMLAB) undervalued?
What is the fair value of UNICHEMLAB?
What is the quality score of UNICHEMLAB?
What is the revenue of Unichem Laboratories Limited (UNICHEMLAB)?
What is the net profit margin of UNICHEMLAB?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.